𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The results of radical prostatectomy at a community hospital during the prostate specific antigen era

✍ Scribed by Melanie C. Smitt; Marianne Heltzel


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
498 KB
Volume
77
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


BACKGROUND.

The use of radical prostatectomy in the treatment of prostate cancer has increased with the advent of prostate specific antigen (PSA) screening. Few series have examined the relapse rates after prostatectomy relative to pre-treatment prognostic factors, such as preoperative PSA and Gleason score. The characteristics and outcome of patients diagnosed with prostate cancer and treated with radical prostatectomy at community hospitals in the prostate specific antigen era have not been described in detail. METHODS. The tumor registry records were obtained for all patients diagnosed with prostate cancer and treated with radical prostatectomy at Washington Hospital, Fremont, CA, from 1990 through 1993. The clinical and pathologic characteristics, including the original pathology reports, for the 100 patients were reviewed by a single physician. Relapse was defined by the persistence or appearance of a PSA value greater than 0.2 ng/mL (Hybritech, Inc., San Diego, CA) following surgery or by clinical evidence of recurrent disease. Crude and actuarial probabilities of relapse were analyzed relative to pre-treatment PSA values, Gleason score, pathologic stage, and surgical margin status. The median follow-up time was 2.5 years.

RESULTS.

The pT-classification distribution of the 100 cases was as follows: T1, 4%; TZA, 14%; T2B, 11%; T2C, 49%; T3A, 8%; T3B, 2%; T3C, 6%; and N+, 6%. Pretreatment PSA values were less than or equal to 4 ng/mL for 10 patients, greater than 4 to 10 ngimL for 38 patients, greater than 10 to 20 ngimL for 27 patients, and greater than 20 ng/mL for 13 patients. The value was unknown for 12 patients. The Gleason score was less than or equal to 5 for 40%, 6 for 17%, 7 for 31%, and 8 to 10 for 12%. Positive surgical margins were noted in 30% of the patients. The actuarial probability of overall survival and freedom from relapse for the entire group of patients at 3 years was 95% and 73%, respectively. Pre-treatment PSA values greater than 20 nglmL, Gleason score greater than or equal to 7, and pT3 classification were significant predictors of relapse in univariate analysis. Preoperative PSA greater than 20 ng/mL and Gleason score were significant prognostic factors in multivariate analysis. Pathologic margin status was not a significant predictor of relapse in this experience. CONCLUSIONS. Short-term relapse rates are high among those patients with preoperative PSA values greater than 20 ng/mL or Gleason scores greater than or equal to 7. Overall results of radical prostatectomy at this community hospital were similar to those reported at referral centers. Cancer 1996; 72928-33.


πŸ“œ SIMILAR VOLUMES


Predictors of prostate-specific antigen
✍ Stephen J. Freedland; William J. Aronson; Joseph C. Presti Jr.,; Christopher L. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Seminal vesicle (SV) invasion at the time of radical prostatectomy (RP) generally is considered to be indicative of poor outcome. The authors examined whether there was a subset of men with SV invasion who had long‐term prostate‐specific antigen (PSA) progression–free sur

Biochemical outcome after radical prosta
✍ Anthony V. D'Amico; Richard Whittington; S. Bruce Malkowicz; Kerri Cote; Marian πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 1 views

## Abstract ## BACKGROUND To the authors' knowledge, consensus is lacking regarding the relative long‐term efficacy of radical prostatectomy (RP) versus conventional‐dose external beam radiation therapy (RT) in the treatment of patients with clinically localized prostate carcinoma. ## METHODS A

A brief review of ultrasensitive prostat
✍ T. K. Takayama; R. L. Vessella; P. H. Lange πŸ“‚ Article πŸ“… 1993 πŸ› Springer-Verlag 🌐 English βš– 406 KB

The development of immunoassays for prostate-specific antigen (PSA) and their clinical utility are summarized. Because of the complexity of the PSA molecule and anti-PSA antibodies, there is currently no standard in PSA measurement [1,2]. Evaluating various immunoassays requires the knowledge of the

The greatest dimension of prostate carci
✍ Atsuko Shibata πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 2 views

The Concept of Tenju-gann, or "Natural-End Cancer" T he concept of Tenju-gann proposed by Kitagawa et al. 1 and dis- cussed in the accompanying editorial by Kennedy 2 deserves broader application than these authors suggest. Although cancer is increasingly an illness of the elderly, there remains a

The greatest dimension of prostate carci
✍ Andrew A. Renshaw; Jerome P. Richie; Kevin R. Loughlin; Michael Jiroutek; Arnold πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 2 views

## BACKGROUND. Tumor volume in radical prostatectomies can be determined by several different techniques and appears to predict clinical progression. Greatest tumor dimension and area are easily obtained measures that are both correlated with tumor volume. The authors sought to determine whether g